{
    "clinical_study": {
        "@rank": "119218", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID\n      2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis"
        }, 
        "brief_title": "TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Active Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Men or women aged 18 to 75 years\n\n          -  Active ulcerative colitis, except proctitis limited to 15 cm ab ano,   confirmed by\n             endoscopy and histology\n\n        Exclusion Criteria:\n\n          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,\n             diverticular disease associated colitis, microscopic colitis (i.e., collagenous\n             colitis and lymphocytic colitis)\n\n          -  Toxic megacolon\n\n          -  Screening stool positive for germs causing bowel disease\n\n          -  Malabsorption syndromes\n\n          -  Celiac disease\n\n          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that\n             may cause diarrhoea or gastrointestinal bleeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745770", 
            "org_study_id": "SAT-25/UCA"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "Mesalazine - TID 1000 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "intervention_name": "Mesalazine - TID 2x 500 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mesalamine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "axel.dignass@fdk.info", 
                "last_name": "Axel Digna\u00df, Prof. Dr.", 
                "phone": "+49 (0)69 953322", 
                "phone_ext": "01"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60431"
                }, 
                "name": "Med. Klinik 1 - Markus-Krankenhaus"
            }, 
            "investigator": {
                "last_name": "Axel Digna\u00df, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With Active Ulcerative Colitis", 
        "overall_contact": {
            "email": "nacak@drfalkpharma.de", 
            "last_name": "Tanju Nacak, Dr.", 
            "phone": "+49 (0)761 1514", 
            "phone_ext": "187"
        }, 
        "overall_contact_backup": {
            "email": "axel.dignass@fdk.info", 
            "last_name": "Axel Digna\u00df, Prof. Dr.", 
            "phone": "+49 (0)69 953322", 
            "phone_ext": "01"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients with clinical remission at week 8 compared to baseline. Clinical remission includes normalisation of stool frequency and absence of blood in stools", 
            "measure": "Rate of clinical remission", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745770"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of stools per week", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Number of bloody stools per week", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Times to first resolution of symptoms defined as the periods from the day of first administration of trial medication , until the\nFirst of at least 3 consecutive days each with =< 3 stools/day\nFirst of at least 3 consecutive days each with no bloody stools/day,\nFirst of at least 3 consecutive days each with =< 3 stools/day, all without blood", 
                "measure": "Time to first resolution of clinical symptoms", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Dr. Falk Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Falk Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}